Skip to Content
MilliporeSigma
All Photos(1)

Documents

C0460000

Carbidopa

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C10H14N2O4 · H2O
CAS Number:
Molecular Weight:
244.24
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carbidopa

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

InChI key

QTAOMKOIBXZKND-PPHPATTJSA-N

Gene Information

human ... DDC(1644)

Looking for similar products? Visit Product Comparison Guide

General description

Carbidopa is a dopaminergic drug, which is known to inhibit the conversion of dopa to dopamine. It is used in combination with levodopa for the effective treatment of restless legs syndrome and periodic leg movements in sleep.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbidopa EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 3

1 of 3

Sigma-Aldrich

Sigma-Aldrich

SML0654

Entacapone

Levodopa Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1271

Levodopa

Àlex Pericas et al.
Organic letters, 15(7), 1448-1451 (2013-03-13)
A stereoselective synthesis of L-carbidopa in seven steps and 50% overall yield from commercial compounds is described. The key step involves a highly enantioselective α-amination reaction of an acyclic β-ketoester with di-tert-butyl azodicarboxylate induced by europium and (R,R)-diphenyl-pybox.
Augmentation of the restless legs syndrome with carbidopa/levodopa
Allen.PR and Earley.JC
Sleep, 19(3), 205-213 (1996)
Hubert H Fernandez et al.
Parkinsonism & related disorders, 19(3), 339-345 (2013-01-05)
Levodopa-carbidopa intestinal gel (LCIG) delivered continuously via percutaneous endoscopic gastrojejunostomy (PEG-J) tube has been reported, mainly in small open-label studies, to significantly alleviate motor complications in Parkinson's disease (PD). A prospective open-label, 54-week, international study of LCIG is ongoing in
Ina Schabram et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(44), 14769-14776 (2014-10-31)
Methylphenidate (MPH) inhibits the reuptake of dopamine and noradrenaline. PET studies with MPH challenge show increased competition at postsynaptic D2/3-receptors, thus indirectly revealing presynaptic dopamine release. We used [(18)F]fluorodopamine ([(18)F]FDOPA)-PET in conjunction with the inlet-outlet model (IOM) of Kumakura et
Kathleen Fagerlund et al.
The American journal of nursing, 113(1), 26-35 (2012-12-19)
Carbidopa-levodopa (Sinemet), the gold-standard treatment for Parkinson's disease, has a short half-life of one to two hours. When patients with Parkinson's disease are placed on NPO (nil per os, or nothing by mouth) status for surgery, they may miss several

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service